Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
- PMID: 2072144
- DOI: 10.1200/JCO.1991.9.8.1403
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
Abstract
Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN alfa-2b. Median time to treatment failure (TTF) and median survival are significantly better on the combination arm, with some long-term CRs observed. More toxicity was encountered in the combination arm, which was acceptable except in three patients where treatment was discontinued because of IFN toxicity.
Similar articles
-
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.J Clin Oncol. 1998 May;16(5):1743-51. doi: 10.1200/JCO.1998.16.5.1743. J Clin Oncol. 1998. PMID: 9586887 Clinical Trial.
-
Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.Med Oncol. 1995 Mar;12(1):35-40. doi: 10.1007/BF01571406. Med Oncol. 1995. PMID: 8542245 Clinical Trial.
-
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.J Clin Oncol. 2010 Apr 1;28(10):1780-7. doi: 10.1200/JCO.2009.25.5208. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194853 Clinical Trial.
-
[Treatment of metastasized malignant melanoma].Praxis (Bern 1994). 2001 Mar 8;90(10):391-6. Praxis (Bern 1994). 2001. PMID: 11305184 Review. German.
-
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.Semin Oncol. 1997 Feb;24(1 Suppl 4):S39-43. Semin Oncol. 1997. PMID: 9122733 Review.
Cited by
-
A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.Cancer Immunol Immunother. 1994 Jun;38(6):379-84. doi: 10.1007/BF01517207. Cancer Immunol Immunother. 1994. PMID: 8205559 Free PMC article. Clinical Trial.
-
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.Br J Cancer. 1998 Apr;77(8):1280-6. doi: 10.1038/bjc.1998.214. Br J Cancer. 1998. PMID: 9579834 Free PMC article. Clinical Trial.
-
Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.Invest New Drugs. 1996;14(2):115-30. doi: 10.1007/BF00210782. Invest New Drugs. 1996. PMID: 8913832 Review.
-
Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.Cancer Immunol Immunother. 1995 Mar;40(3):157-64. doi: 10.1007/BF01517347. Cancer Immunol Immunother. 1995. PMID: 7728774 Free PMC article. Clinical Trial.
-
Immunotherapy of distant metastatic disease.Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi41-50. doi: 10.1093/annonc/mdp253. Ann Oncol. 2009. PMID: 19617297 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
